Advertisement

3 Stocks You Can Still Buy on Sale in a Ridiculously Expensive Market

3 Stocks You Can Still Buy on Sale in a Ridiculously Expensive Market

The big pharma stock is priced so low mainly because investors are worried about AbbVie's growth prospects once top-selling autoimmune disease drug Humira begins to face biosimilar rivals in the U.S. in 2023. Although that's a legitimate concern, it's important to look at the big picture for AbbVie. First of all, Humira's sales will certainly decline significantly but won't evaporate overnight.